Article

Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients

2020-08-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 22f796bd-0150-5c7f-a1cf-19a1f5cf5234
DOI: 10.1016/s0168-8278(20)30647-4

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patientsDOI 10.1016/s0168-8278(20)30647-4Read

Advances with RNAi-Based Therapy for Hepatitis B Virus InfectionSemantic proximity Read

Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?Semantic proximity Read

Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA.Semantic proximity Read

RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future ProspectsSemantic proximity Read

Investigational RNA Interference Agents for Hepatitis BSemantic proximity Read

Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNASemantic proximity Read

Opportunities for treating chronic hepatitis B and C virus infection using RNA interferenceSemantic proximity Read

Countering hepatitis B virus infection using RNAi: how far are we from the clinic?Semantic proximity Read

The progress of molecules and strategies for the treatment of HBV infectionSemantic proximity Read

Progress and Prospects of Anti-HBV Gene Therapy DevelopmentSemantic proximity Read

Molecular therapeutics of HBV.Semantic proximity Read

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intentSemantic proximity Read